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Human DNA methylation data have been used to develop biomarkers of ageing, referred to as ‘epigenetic clocks’, which have been
widely used to identify differences between chronological age and biological age in health and disease including neurodegeneration,
dementia and other brain phenotypes. Existing DNA methylation clocks have been shown to be highly accurate in blood but are
less precise when used in older samples or in tissue types not included in training the model, including brain. We aimed to develop
a novel epigenetic clock that performs optimally in human cortex tissue and has the potential to identify phenotypes associated
with biological ageing in the brain. We generated an extensive dataset of human cortex DNA methylation data spanning the life
course (n = 1397, ages = 1 to 108 years). This dataset was split into ‘training’ and ‘testing’ samples (training: n = 1047; testing:
n = 350). DNA methylation age estimators were derived using a transformed version of chronological age on DNA methylation at
specific sites using elastic net regression, a supervised machine learning method. The cortical clock was subsequently validated in a
novel independent human cortex dataset (n = 1221, ages = 41 to 104 years) and tested for specificity in a large whole blood dataset
(n = 1175, ages = 28 to 98 years). We identified a set of 347 DNA methylation sites that, in combination, optimally predict age in
the human cortex. The sum of DNA methylation levels at these sites weighted by their regression coefficients provide the cortical
DNA methylation clock age estimate. The novel clock dramatically outperformed previously reported clocks in additional cortical
datasets. Our findings suggest that previous associations between predicted DNA methylation age and neurodegenerative pheno-
types might represent false positives resulting from clocks not robustly calibrated to the tissue being tested and for phenotypes that
become manifest in older ages. The age distribution and tissue type of samples included in training datasets need to be considered
when building and applying epigenetic clock algorithms to human epidemiological or disease cohorts.
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Introduction
Advancing age is associated with declining physical and cog-
nitive function, and is a major risk factor for many human
brain disorders including dementia and other neurodegener-
ative diseases (Harper, 2014; Sierra, 2019). Understanding
the biological mechanisms involved in ageing will be a critic-
al step towards preventing, slowing or reversing age-associ-
ated phenotypes. Because of substantial inter-individual
variation in age-associated phenotypes, there is considerable
interest in identifying robust biomarkers of ‘biological’ age,
a quantitative phenotype that is thought to better capture an
individual’s risk of age-related outcomes than actual chrono-
logical age (Jylhävä et al., 2019). Several data modalities
have been used to generate estimates of biological age; these
include measures of physical fitness (e.g. muscle strength)
(Sosnoff and Newell, 2006), cellular phenotypes (e.g. cellular
senescence) (Baker et al., 2011), genomic changes (e.g. telo-
mere length) (Sanders and Newman, 2013; Jylhävä et al.,
2017) and epigenetic mechanisms (e.g. DNA methylation)
(Horvath, 2013).
Epigenetic mechanisms act to regulate gene expression
developmentally via chemical modifications to DNA and
histone proteins (Bernstein et al., 2007), conferring cell-type-
specific patterns of gene expression and differing markedly
between tissues and cell types (Mendizabal and Yi, 2016).
There has been recent interest in the dynamic changes in
epigenetic processes over the life course, and a number of
‘epigenetic clocks’ based on one specific epigenetic modifica-
tion, DNA methylation (DNAm), have been developed that
appear to be highly predictive of chronological age
(Hannum et al., 2013; Horvath, 2013). The landmark
DNAm clock was developed by Horvath (2013), who
applied elastic net regression to Illumina DNAm array data
from a large number of samples derived from a range of tis-
sues (n = 8000 across 51 tissue and cell types), and gener-
ated a predictor based on DNAm at 353 CpG sites that is
highly predictive of chronological age (Horvath, 2013).
Given that changes in DNAm are known to index exposure
to certain environmental risk factors (for example, tobacco
smoking) (Elliott et al., 2014; Sugden et al., 2019) that are
associated with diseases of old age, and variable DNAm is
robustly associated with a number of age-associated disor-
ders (Smith et al., 2016; Chuang et al., 2017; Chouliaras
et al., 2018), there has been interest in the hypothesis that
DNAm clocks might robustly quantify variation in
biological age. Horvath’s DNAm age clock, for example,
has been widely applied to identify accelerated epigenetic
ageing, where DNAm age predictions deviate from chrono-
logical age such that individuals appear older than they real-
ly are, in the context of numerous health and disease
outcomes (Horvath and Ritz, 2015; Levine et al., 2015;
Marioni et al., 2015; McCartney et al., 2018). Although the
original DNAm clocks were primarily developed to predict
chronological age and are not robustly predictive of clinical
health measures (e.g. blood pressure) (Quach et al., 2017),
more recent DNAm clocks such as Levine’s ‘pheno age’
clock (Levine et al., 2018) incorporate surrogate measures of
biological age and are more directly aimed at predicting
mortality and healthspan. Since age is a major risk factor for
dementia and other neurodegenerative brain disorders, there
is particular interest in the application of epigenetic clock
algorithms to these phenotypes, especially as differential
DNAm in the cortex has been robustly associated with dis-
eases including Alzheimer’s disease and Parkinson’s disease
(Lunnon et al., 2014; Yu et al., 2015; Smith et al., 2016).
Recent studies have reported an association between acceler-
ated DNAm age and specific markers of Alzheimer’s disease
neuropathology in the cortex (e.g. neuritic plaques, diffuse
plaques and amyloid-b load) (Levine et al., 2015, 2018).
Furthermore, among individuals with Alzheimer’s disease,
DNAm age acceleration is associated with declining global
cognitive functioning and deficits in episodic and working
memory (Levine et al., 2015, 2018).
A strength of several existing epigenetic clocks is that they
work relatively well across different types of sample; the
Horvath multi-tissue clock, for example, can accurately pre-
dict age in multiple tissues across the life course.
Importantly, as with any predictor, the composition of the
training data used to develop the clock influences the gener-
ality of the model. To date, there has been limited research
comparing the prediction accuracy and potential bias of
existing clock algorithms across different tissues and ages.
Recent analyses have highlighted potential biases when using
Horvath’s clock in older samples (460 years) and in sam-
ples derived from certain tissues, especially the CNS (El
Khoury et al., 2019). This is important for the interpretation
of studies of possible relationships between accelerated epi-
genetic age and age-related diseases affecting the human
brain (e.g. neurodegenerative phenotypes); reported associa-
tions between accelerated DNAm age and disease may actu-
ally be a consequence of fitting a suboptimal predictor to
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available datasets. Potential confounders include differential
changes in DNAm with age across tissues, and the age distri-
bution of the samples used to train existing classifiers.
Resolution of these biases requires the construction of specif-
ic DNAm clocks developed using data generated on the rele-
vant tissue-type and including broad representation of the
age spectrum they will be used to interrogate. Recently, a
number of tissue-specific DNA methylation clocks have been
described, including clocks designed for whole blood
(Hannum et al., 2013; Zhang et al., 2019), muscle (Voisin
et al., 2020), bone (Gopalan et al., 2019) and paediatric
buccal cells (McEwen et al., 2019). Importantly, although
these DNAm age estimators have increased predictive accur-
acy within the specific tissues in which they were built, they
lose this precision when applied to other tissues (Zhang
et al., 2019).
In this study, we describe the development of a novel
DNAm clock that is specifically designed for application in
DNA samples isolated from the human cortex and is accur-
ate across the lifespan including in tissue from older donors
(aged over 60 years). We demonstrate that our clock outper-
forms existing DNAm-based predictors developed for other
tissues, minimizing the potential for spurious associations
with ageing phenotypes relevant to the brain.
Materials and methods
Datasets used to develop the novel
cortical DNAm age clock
To develop and characterize our cortical DNAm age clock
(‘DNAmClockCortical’) we collated an extensive collection of
DNAm data from human cortex samples (Supplementary
Tables 1 and 2), complementing datasets generated by our
group (http://www.epigenomicslab.com) with publicly available
datasets downloaded from the Gene Expression Omnibus
(GEO; https://www.ncbi.nlm.nih.gov/geo/) (Jaffe et al., 2016; De
Jager et al., 2014; Lunnon et al., 2014; Pidsley et al., 2014;
Smith et al., 2018, 2019; Wong et al., 2019) (Supplementary
Tables 1 and 2). In each of these datasets DNAm was quantified
across the genome using the Illumina 450K DNA methylation
array, which covers 4450 000 DNA methylation sites as
previously described (Pidsley et al., 2013). To optimize the per-
formance of the DNAmClockCortical and to avoid reporting
over-fitted statistics, the samples were split into a ‘training’ data-
set (used to determine the DNAm sites included in the model
and their weighted coefficients) and a ‘testing’ dataset (used to
profile the performance of the proposed model). To reduce the
effects of experimental batch in our model, we maximized the
number of different datasets included in the training data by
combining the 10 cohorts and randomly assigning individuals
within them to either the training or testing dataset in a 3:1
ratio (Table 1). In total, our training dataset (age range =
1–108 years, median = 57 years; Supplementary Fig. 1) com-
prised DNAm data from 1047 cortex samples (derived from
832 donors) and our testing dataset (age range = 1–108 years,
median = 56 years; Supplementary Fig. 1) comprised DNAm
data from 350 cortex samples (derived from 323 donors).
Individuals with a diagnosis of Alzheimer’s disease and other
major neurological phenotypes were excluded from our analysis
given the previous associations between them and deviations in
DNAm age (Levine et al., 2015, 2018).
Cortex independent test dataset
An ‘independent test’ cortical dataset was generated using post-
mortem occipital and prefrontal cortex samples from the Brains
for Dementia Research (BDR) cohort. BDR was established in
2008 and is a UK-based longitudinal cohort study with a focus
on dementia research (Francis et al., 2018) coordinated by a net-
work of six dementia research centres located around the UK.
Post-mortem brains underwent full neuropathological dissection,
sampling and characterization using a standardized protocol (Bell
et al., 2008; Samarasekera et al., 2013). DNA was isolated from
cortical tissue samples using the Qiagen AllPrep DNA/RNA 96
Kit (Qiagen, cat no. 80311) following tissue disruption using
BeadBug 1.5 mm Zirconium beads (Sigma Aldrich, cat no.
Z763799) in a 96-well deep well plate (Fisher Scientific, cat no.
12194162) shaking at 2500 rpm for 5 min. Genome-wide DNA
methylation was profiled using the Illumina EPIC DNA methyla-
tion array (Illumina Inc), which interrogates 4850 000 DNA
methylation sites across the genome (Moran et al., 2016). After
stringent data quality control (see below) the final independent
test dataset consisted of DNAm estimates for 800 916 DNAm
sites profiled in 1221 samples (632 donors; 610 prefrontal cortex;
611 occipital cortex; see Table 1 for more details). This dataset
consists of predominantly older samples (age range = 41–104
years, median = 84 years; Supplementary Fig. 1).
Whole blood dataset
We recently generated DNAm data from whole blood obtained
from 1175 individuals (age range = 28–98 years; median age =
59 years; Table 1) included in the UK Household Longitudinal
Study (UKHLS) (https://www.understandingsociety.ac.uk/)
(Hannon et al., 2018). The UKHLS was established in 2009
and is a longitudinal panel survey of 40 000 UK households
from England, Scotland, Wales and Northern Ireland (Buck and
McFall, 2011). For each participant, non-fasting blood samples
were collected through venepuncture; these were subsequently
centrifuged to separate plasma and serum, and samples were ali-
quoted and frozen at –80C. DNAm data were generated using
the Illumina EPIC DNA methylation array as described previ-
ously (Hannon et al., 2018). After stringent quality control (see
below) the whole blood dataset consisted of data for 857 071
DNAm sites profiled in 1175 samples (Hannon et al., 2018).
DNA methylation data
preprocessing
Unless otherwise reported, all statistical analysis was conducted
in the R statistical environment (version 3.5.2; https://www.r-
project.org/). Raw data for all datasets were used, prior to any
quality control or normalization, and processed using either the
wateRmelon (Pidsley et al., 2013) or bigmelon (Gorrie-Stone
et al., 2019) packages. Our stringent quality control pipeline
included the following steps: (i) checking methylated and unme-
thylated signal intensities and excluding poorly performing sam-
ples; (ii) assessing the chemistry of the experiment by calculating
a bisulphite conversion statistic for each sample, excluding
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samples with a conversion rate 580%; (iii) identifying the fully
methylated control sample was in the correct location (where
applicable); (iv) multidimensional scaling of sites on the X and
Y chromosomes separately to confirm reported sex; (v) using
the 65 single nucleotide polymorphism (SNP) probes present on
the Illumina 450K array and 59 on the Illumina EPIC array to
confirm that matched samples from the same individual (but dif-
ferent brain regions) were genetically identical and to check for
sample duplications and mismatches; (vi) use of the pfilter()
function in wateRmelon to exclude samples with 41% of
probes with a detection P-value40.05 and probes with 41%
of samples with detection P-value 4 0.05; (vii) using principal
component analysis on data from each tissue to exclude outliers
based on any of the first three principal components; and (viii)
removal of cross-hybridizing and SNP probes (Chen et al.,
2013). The subsequent normalization of the DNA methylation
data was performed using the dasen() function in either
wateRmelon or bigmelon (Pidsley et al., 2013; Gorrie-Stone
et al., 2019).
Deriving a novel cortical DNAm
age classifier
To build the DNAmClockCortical we implemented an elastic net
regression model, using the methodology described by Horvath
(2013). The elastic net model is designed for high dimensional
datasets with more features than samples and where the features
are potentially highly correlated (Zou and Hastie, 2005). As
part of the methodology, the model selects the subset of features
(i.e. DNAm sites) that cumulatively produce the best predictor
of a provided outcome. Elastic net was implemented in the R
package GLMnet (Friedman et al., 2010). It uses a combination
of Ridge and LASSO (least absolute shrinkage and selection op-
erator) regression. Ridge regression penalizes the sum of squared
coefficients and has an (alpha) parameter of 0. LASSO regres-
sion penalises the sum of the absolute values of the coefficients
and has an a parameter of 1. Elastic net is a convex combin-
ation of ridge and LASSO and, therefore, the elastic net a par-
ameter was set to 0.5. The lambda value (the shrinkage
parameter) was derived using 10-fold cross-validation on the
training dataset (lambda = 0.0178). DNAm probes included in
the analysis were limited to sites which were present on both
the Illumina EPIC and Illumina 450K arrays, with no missing
values across the training datasets (n probes = 383 547).
Previous analyses have shown that the relationship between
DNAm age (predicted age from epigenetic age estimators) and
chronological age is logarithmic between 0 and 20 years and lin-
ear from 20 years plus (Horvath, 2013). Our data revealed a
similar pattern and therefore chronological age was transformed
(Supplementary Fig. 2). A transformed version of chronological
age was regressed on DNAm levels at all included DNAm sites.
Implementing DNAm Age
prediction
We applied the DNAmClockCortical (comprising 347 DNAm
sites) to the testing, independent test and whole blood DNAm
datasets. We then compared its performance to a number of
existing DNAm clocks which have previously shown biases
when applied to brain tissue and older samples (Horvath and
Raj, 2018; El Khoury et al., 2019; Zhang et al., 2019):
Horvath’s original multi-tissue clock (‘DNAmClockMulti’; 353
DNAm sites) (Horvath, 2013), Zhang’s elastic net blood and
saliva-based DNAm clock (‘DNAmClockBlood’: 514 DNAm
sites) (Zhang et al., 2019) and Levine’s second generation
‘pheno age’ DNAm Clock (‘DNAmClockPheno’; 513 DNAm
sites) (Levine et al., 2018). Briefly, to predict DNAm age using
the DNAmClockMulti we applied the agep() function in
wateRmelon (Pidsley et al., 2013). Although this function does
not contain the custom normalization method applied at the
DNAm age calculator website (https://DNAmClock.genetics.
ucla.edu/), both methods work similarly in brain and blood
studies, providing the data have been preprocessed adequately
(El Khoury et al., 2019). To predict age using the
DNAmClockPheno (Levine et al., 2018), we also applied the
agep() function, inputting a vector of the coefficients and the
intercept using the data provided in the supplementary material
of Levine et al’s paper. To predict DNAm age with the
DNAmClockBlood, we used the authors’ published code
Table 1 Sample characteristics of the training (cortex), testing (cortex), independent test (cortex) and whole blood
datasets used in the development and evaluation of DNAmClockCortical




n Mean 1st Quartile Median 3rd Quartile Range Female Male
Training 1047 56.53 38.56 57 78 1–108 362 685 450K De Jager et al., 2014; Lunnon
et al., 2014; Pidsley et al.,
2014; Jaffe et al., 2016; Smith
et al., 2018, 2019; Wong
et al., 2019
Testing 350 55.87 39.05 56 78 1–108 144 206 450K De Jager et al., 2014; Lunnon
et al., 2014; Pidsley et al.,
2014; Jaffe et al., 2016; Smith
et al., 2018, 2019; Wong
et al., 2019
Independent test 1221 83.49 78 84 90 41–104 577 644 EPIC –
Blood 1175 57.96 46 59 69 28–98 686 489 EPIC Hannon et al., 2018
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(available on GitHub https://github.com/qzhang314/DNAm-
based-age-predictor) (Zhang et al., 2019).
Determining the predictive
accuracy of different DNAm clocks
DNAm age was estimated in the testing dataset (n = 350), inde-
pendent test dataset (n = 1221) and whole blood dataset
(n = 1175) using DNAmClockCortical, DNAmClockMulti,
DNAmClockBlood and DNAmClockPheno. To compare and
evaluate the predictive accuracy of these DNAm age predictors,
estimates were assessed using two measures: Pearson’s correl-
ation coefficient [r; a measure indicating the strength of the lin-
ear relationship between the actual (chronological age) and
predicted (DNAm age) variables] and the root mean squared
error (RMSE; square root of the mean differences between the
actual and predicted variables), which quantifies the precision of
the estimator.
Analysis against age
To test associations between DNAm age and chronological age,
we fitted regression models to each dataset. As a subset of
donors included in the testing and independent test datasets con-
tributed data from multiple cortical regions, we used mixed
effects linear regression models, implemented with the lme4 and
lmerTest packages, where DNAm age was regressed against
chronological age as a fixed effect and individual was included
as a random effect. In the blood cohort, as there was only one
sample per individual, we applied standard linear regression
models. A second regression model was also fitted which add-
itionally tested for associations with an age-squared term. In the
whole blood dataset, we ran these analyses again in the subset
of samples over 55 years old to make the results more compar-
able to those generated using the independent test dataset.
Analysis against biological and
technical factors
To test associations between DNAm age and sex, post-mortem
interval, experimental batch and neuronal cell proportion esti-
mates [derived using the CETS algorithm (Guintivano et al.,
2013)] we fitted regression models to the independent test data-
set (n = 1221 cortical samples). We used mixed effects regression
models implemented as described above. DNAm age was
regressed against each variable in turn with age, age squared
and derived cell proportion estimates (excluding the model look-
ing for associations with cell proportions) as fixed effects and in-
dividual as random effect. In the analysis with post-mortem
interval we included brain bank as a fixed effect.
Data availability
The datasets used for the training and testing samples are avail-
able for download from GEO (https://www.ncbi.nlm.nih.gov/
geo/) using the following accession numbers: GSE74193;
GSE59685; GSE80970; GPL13534 and GSE43414. The inde-
pendent test data are available from the authors upon request
or via the Dementias Platform UK (DPUK) data portal (https://
portal.dementiasplatform.uk/). The whole blood DNA methyla-
tion data are available upon application through the European
Genome-Phenome Archive under accession code
EGAS00001001232. Analysis scripts used in this manuscript
and code to run the clock are available on GitHub (https://
github.com/gemmashireby/CorticalClock).
Results
Existing human cortex DNAm clock
algorithms systematically
underestimate age in older
individuals
The performance of DNAm clocks is influenced by the char-
acteristics (e.g. specific tissue type and age range) of the train-
ing data used to build the prediction algorithm. Applying
predictors to datasets that differ in terms of these characteris-
tics may lead to biases when estimating DNAm age, and con-
found phenotypic analyses using these variables (El Khoury
et al., 2019). We found that existing DNAm clocks [i.e. the
DNAmClockMulti (Horvath, 2013) the DNAmClockBlood
(Zhang et al., 2019) and the DNAmClockPheno (Levine et al.,
2018)] do not perform optimally in human cortex tissue
(Supplementary Fig. 3), with notable differences between
derived DNAm age and actual chronological age (i.e. the
derived values do not lie along the y = x line; Fig. 1). In our
testing dataset (n = 350 cortex samples; age range = 1–108
years; median age = 57 years), the DNAmClockMulti system-
atically underestimated DNAm age in individuals over 60
years old, and systematically overestimated it in individuals
below 60 years old [Figs 1A(ii) and 2A(ii)]. In the older
group (aged over 60 years), around 80% of samples had
lower predicted DNAm ages than their actual chronological
age. These deviations were also observed when looking at
the mean differences between actual age and predicted
DNAm age [referred to as D (delta) age), such that D age
was positive for younger ages and vice versa for the older
group (Supplementary Fig. 4A). Use of the DNAmClockBlood
produced even more pronounced systematic underestimation
of DNAm age in adults, beginning around 30 years
[Figs 1A(iii) and 2A(iii)], and this trend was mirrored for D
age (Supplementary Fig. 4A). Finally, the DNAmClockPheno
severely under predicted age in the cortex, with 100% of
samples being assigned a lower DNAm age than the actual
chronological age [Figs 1A(iv), 2A(iv) and Supplementary
Fig. 4A(iv)]. Similar biases in age prediction were seen in our
independent test dataset (n = 1221 cortex samples; age range
= 41 years to 104 years; mean age = 83.49 years), confirm-
ing the systematic underestimation of DNAm age in older
donors (Figs 1B and 2B). As with the other clocks, D age
captured these biases, with particularly poor performance
evident when applying the DNAmClockPheno and the
DNAmClockBlood to this dataset, in which D age was consist-
ently below zero (where zero would represent perfect predic-
tion; see Supplementary Fig. 4B).
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Developing a novel DNAm clock for
the human cortex based on DNA
methylation sites
To alleviate the biases observed when applying existing
DNAm clocks to data generated on older human cortex
samples, we focused on building a DNAm clock using
relevant tissue samples from donors that spanned a
broad range of ages and included a large number of
samples from older donors (Supplementary Fig. 1). We
developed our novel cortical DNAm clock
(DNAmClockCortical) using an elastic net regression,
regressing chronological age against DNAm levels across
383 547 sites quantified in 1047 cortex samples (see
‘Materials and methods’ section). This approach identi-
fied a set of 347 DNAm sites, which in combination,
optimally predict age in the human cortex. The sum of
DNAm levels at these sites weighted by their regression
coefficients provides the DNAmClockCortical age estimate
(Supplementary Table 3). Of note, the majority of sites
selected for our cortex clock were novel and not present
in existing DNAm clock algorithms; only five of the
sites overlap with the DNAmClockMulti (composed of
353 DNAm sites), 15 with the DNAmClockBlood (com-
prising 514 DNAm sites), and five with the
DNAmClockPheno (comprising 513 DNAm sites)
(Supplementary Table 4).
Increased prediction accuracy of the
novel cortex clock in cortical tissue
compared to existing DNAm clocks
We used DNAmClockCortical to estimate DNAm age in both
the testing (n = 350 cortex samples) and independent test
(n = 1221 cortex samples) datasets, and compared the esti-
mates to those derived using DNAmClockMulti,
DNAmClockBlood and DNAmClockPheno. The DNAm
ClockCortical predicted age accurately in the testing dataset
and there was a strong correlation between DNAm age and
age [r = 0.99; Table 2 and Fig. 1A(i)]. In the independent
test dataset, which consisted predominantly of older
Figure 1 Comparison of chronological age with DNA methylation age derived using four DNA methylation age clocks.
Shown are comparisons of chronological age with predicted age in (A) the testing dataset (n = 350 cortical samples) and (B) the independent
test dataset (n = 1221 cortical samples). DNAm age was predicted using four DNA methylation age clocks: (i) our novel DNAmClockCortical;
(ii) Horvath’s DNAmClockMulti; (iii) Zhang’s DNAmClockBlood and (iv) Levine’s DNAmClockPheno. The x-axis represents chronological age
(years) and the y-axis represents predicted age (years). Each point on the plot represents an individual sample. Our cortical clock out-performed
the three alternative DNAm clocks across all accuracy statistics. DNA methylation age estimates derived using the DNAmClockMulti [A(ii) test-
ing and B(ii) independent test] and the DNAmClockBlood [A(iii) testing and B(iii) independent test] appear to have a non-linear relationship
with chronological age.
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samples, our clock also performed well and was highly cor-
related with age (r = 0.83), outperforming DNAmClockMulti
(r = 0.65), DNAmClockBlood (r = 0.52), and DNAm
ClockPheno (r = 0.32) [Table 2 and Fig. 1B(i)]. The most
striking differences were in the accuracy of the
DNAmClockCortical in comparison to previously developed
DNAm clocks; it outperformed the three other clocks we
tested across all accuracy statistics in both cortical datasets
(Table 2). The biggest differences in accuracy can be seen in
the independent test dataset (Figs 1B, 2B and Supplementary
Fig. 4B), in which the RMSE was 15 years more accurate
when using the DNAmClockCortical (RMSE: 5 years) than
the DNAmClockMulti (RMSE: 20 years), 28 years more ac-
curate than the DNAmClockBlood (RMSE: 33 years) and 77
years more accurate than the DNAmClockPheno (RMSE: 82
years). This is further supported by analysing how much of
the variation in DNAm age is explained by age, where the
DNAmClockCortical was the best fitting model in both cor-
tical datasets (testing dataset R2 = 0.98 independent test
sample R2 = 0.65) in comparison to the three other clocks,
with age explaining the least variance in DNAm age esti-
mated using the DNAmClockPheno (testing dataset R
2 =
0.65; independent test sample R2 = 0.10) (Table 2). The
DNAmClockPheno was consistently the most inaccurate at
estimating age in the cortical datasets (RMSE: testing 60
years; independent test 82 years), followed by
DNAmClockBlood (RMSE: testing = 19 years; independent
test = 33 years) and the DNAmClockMulti (RMSE: testing =
10 years; independent test = 20 years) (Table 2).
The relationship between age and
DNAmClock plateaus in old age
By definition, DNAm age is correlated with chronological
age, meaning age is a potential confounder for analyses of D
age; not adequately controlling for age increases the likeli-
hood that false positive associations will be identified (El
Khoury et al., 2019). To assess associations between DNAm
age and chronological age we used a mixed effects regression
model (see ‘Materials and methods’ section) and found that
estimates from all four DNAm age clocks were significantly
associated with age in the testing dataset (Bonferroni
P5 0.005; Table 3). Many studies of D age in health and
disease control for age by using a linear model to regress out
its effect (Marioni et al., 2015; McKinney et al., 2018) al-
though one of the assumptions of this approach is that the
prediction accuracy of the DNAm clock is consistent across
the life course. If the accuracy varies non-linearly with
chronological age, then simply including age as a linear
covariate in association analyses will not sufficiently negate
the confounding effect of age. We therefore sought to for-
mally test the extent to which the prediction accuracy of the
four clocks correlates with age by including an age squared
term in the regression model. In the testing dataset all four
clocks had a significant age squared term (Table 3), indicat-
ing that their predictive accuracy varies as a function of age.
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the difference between DNAm age and chronological age
becomes larger as actual age increases (Fig. 2). Importantly,
however, of the three first generation clocks the coefficient
for the age squared term was smallest for the
DNAmClockCortical (beta = –1.64  10–3, P = 1.94  10–7),
again highlighting that bespoke clocks can be used to min-
imize bias in subsequent analyses.
Higher cortical DNAm age is
associated with decreased neuronal
cell proportions
Many sample-related and technical factors can influence
analyses of DNAm in post-mortem cortex tissue including
sex, neuronal cell proportions, post-mortem interval and ex-
perimental batch effects. To assess associations between
DNAm age and these variables we used a mixed effects
regression model (see ‘Materials and methods’ section) and
after correcting for multiple comparisons (P5 0.005) found
no association between DNAm age and sex (P = 0.03), post-
mortem interval (P = 0.54) or batch (P = 0.38)
(Supplementary Table 5). In contrast there was a significant
association between neuronal cell proportion estimates derived
from the DNAm data (beta = –8.72, P = 9.57  10–36;
Supplementary Table 5) and DNAm age, indicating that
individuals who are predicted as older using the
DNAmClockCortical have lower neuronal cell proportions.
This correlation is not surprising as other clocks have been
widely reported to associate with differences in cell-type
proportions (Horvath and Ritz, 2015; Levine et al., 2018)
and it is known that the proportion of neuronal cells in the
cortex changes with age. This result highlights the import-
ance of, where possible, including cellular proportion varia-
bles as a covariate in any downstream analyses performed
using DNAm clocks on tissue from the human brain.
Figure 2 The cortical DNA methylation age clock has elevated accuracy in human cortex samples across the lifespan. Shown is
the distribution of the error (DNA methylation age – chronological age) for each age decile in (A) the testing dataset (n = 350 cortical samples),
and (B) the independent test dataset (n = 1221 cortical samples) for each of the four DNA methylation age clocks: (i) our novel
DNAmClockCortical; (ii) Horvath’s DNAmClockMulti; (iii) Zhang’s DNAmClockBlood and (iv) Levine’s DNAmClockPheno. Deciles were calculated
by assigning chronological age into 10 bins and are represented along the x-axis by the numbers 1 to 10, followed by parentheses, which display
the age range included in each decile. The ends of the boxes are the upper and lower quartiles of the errors, the horizontal line inside the box
represents the median deviation and the two lines outside the boxes extend to the highest and lowest observations. Outliers are represented by
points beyond these lines. The red horizontal line represents perfect prediction (zero error). Our novel DNAmClockCortical [A(i) testing and
B(i) independent test] consistently had the smallest error across the age groups, shown by the tightness of the box plot distributions along the
zero-error line. The DNAmClockMulti over-predicted younger ages [deciles 1–5 in A(ii)], shown by box plot distributions that are above the
zero-error line, and under predicted older ages [deciles 8–10 in A(ii) and deciles 1–10 in B(ii)], shown by box plot distributions below the zero-
error line. The DNAmClockBlood [A(iii) testing and B(iii) independent test] and the DNAmClockPheno [A(iv) testing and B(iv) independent
test] consistently under predicted age, with under prediction of DNA methylation age increasing with chronological age.
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The cortical clock loses accuracy
when applied to non-cortical tissues
To assess the specificity of the novel cortex clock we next
applied each of the DNAm age clocks to a large whole
blood DNAm dataset (n = 1175; age range = 28–98 years;
mean age = 57.96 years). Although the DNAmClockCortical
performed remarkably well on whole blood (r = 0.88), with
a similar predictive ability to the DNAmClockMulti (r = 0.90)
(Fig. 3 and Supplementary Fig. 5), there was a non-linear re-
lationship between DNAm age and age estimated using this
clock and a systematic under prediction of DNAm age in
samples from individuals aged over 60 years [Fig. 3A(i) and
B(i)]. The DNAmClockBlood performed best on the blood
dataset (r = 0.97), with age explaining the highest proportion
of variation in DNAm age (R2 = 0.94), outperforming the
three other clocks (Table 4, Fig. 3 and Supplementary Figs 5
and 6), and providing further support for the notion that
epigenetic clocks work optimally for the tissue-type on
which they are calibrated. Of note, when limiting the age
range of samples included in the blood cohort to be more
comparable to the independent test dataset (age range lim-
ited to 455 years), the relationship between estimated and
actual age is considerably lower for the three non-blood-spe-
cific clocks (r  0.7) and the DNAmClockBlood (r = 0.88),
reflecting the lower variability of age across samples in the
dataset (Supplementary Fig. 7).
Discussion
Existing DNAm age clocks have been widely used for pre-
dicting age and exploring accelerated ageing in disease, al-
though there is evidence of systematic underestimation of
DNAm age in older samples, particularly in the brain (El
Khoury et al., 2019). We developed a novel epigenetic age
model specifically for human cortex, DNAmClockCortical,
built using an extensive collection of DNAm data from
41000 human cortex samples. Our model dramatically out-
performs existing DNAm-based biomarkers for age predic-
tion in data derived from the human cortex.
There are several potential causes of the systematic under-
estimation of DNAm age in the cortex, especially in samples
from older donors (aged over 60 years), when using existing
DNAm clocks such as Horvath’s DNAmClockMulti
(Horvath, 2013), Zhang’s DNAmClockBlood (Zhang et al.,
2019) and Levine’s DNAmClockPheno (Levine et al., 2018).
First, it may be a consequence of the distribution of ages in
the training data used in existing clocks; these clocks were
derived using samples containing a relatively small propor-
tion of samples from human brain and/or from older sub-
jects. Second, as there is evidence for cell-type and tissue-
specific patterns of DNAm (Mendizabal et al., 2019), the
observed imprecision may reflect a consequence of underfit-
ting the model across tissues. Third, the relationship between
DNA methylation and age may not be linear across the life-
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attenuated effects in older samples. This would be compar-
able to the transformation required to accurately predict
DNAm age for younger samples (0–20 years), where the as-
sociation between age and with DNA methylation is of
larger magnitude.
Our data suggest that both tissue-specificity and the age of
samples included in the training dataset influence the preci-
sion of DNAm age estimators, as shown by the increase in
accuracy when using our cortical clock relative to existing
clocks in human cortex tissue samples. This notion is further
supported by the accuracy we found using the blood-based
estimators on a large blood dataset. Our observations sug-
gest that tissue type has a major influence on the accuracy of
DNAm age clocks, and to accurately predict age it is import-
ant to use a clock calibrated specifically for the tissue from
which samples have been derived. Our data demonstrate
Figure 3 The blood-based DNA methylation clock performs best in data derived from whole blood samples. (A) Shown is a com-
parison of DNA methylation age estimates against chronological age in a large whole blood dataset (n = 1175), where DNAm age derived using
four DNA methylation age clocks: (i) our novel DNAmClockCortical; (ii) Horvath’s DNAmClockMulti; (iii) Zhang’s DNAmClockBlood and (iv)
Levine’s DNAmClockPheno. The x-axis represents chronological age (years), the y-axis represents predicted age (years). Each point on the plot
represents an individual in the whole blood dataset. Our novel clock does not predict as well in blood compared to the cortex, although it has a
similar predictive ability to Horvath’s clock. The distribution of the error (DNA methylation age – chronological age) is presented in B for each
decile for each of the four DNA methylation clocks. Deciles were calculated by assigning chronological age into 10 bins and are represented along
the x-axis by the numbers 1 to 10, followed by parentheses, which display the age range included in each decile. The ends of the boxes are the
upper and lower quartiles of the errors, the horizontal line inside the box represents the median deviation and the two lines outside the boxes
extend to the highest and lowest observations. Outliers are represented by points beyond these lines. The red horizontal line represents perfect
prediction (zero error).
Table 4 The cortex clock is less accurate at estimating DNA methylation age algorithms in blood compared to cor-
tex tissue samples
DNAmClockCortical DNAmClockMulti DNAmClockBlood DNAmClockPheno
Correlation (r) 0.88 0.90 0.97 0.87
RMSE, years 10.79 7.32 3.95 11.70
Accuracy statistics between DNAm age estimates and chronological age using using our DNAmClockCortical, Horvath’s multi-tissue clock (DNAmClockMulti) (Horvath, 2013),
Zhang’s elastic net blood clock (DNAmClockBlood) (Zhang et al., 2019) and Levine’s Pheno Age clock (DNAmClockPheno) (Levine et al., 2018) in our blood dataset (n = 1175 whole
blood samples). RMSE = root mean squared error.
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that the performance of existing DNAm clocks varies con-
siderably across ages and is diminished in samples from
older donors. This is particularly important to consider
when assessing DNAm age in the context of diseases and
phenotypes that are associated with older age such as de-
mentia and other types of neurodegenerative disease. Our
results show that it is important to use a clock that has been
trained using samples from the relevant age group; the train-
ing data used in the development of the DNAmClockCortical
included a good representation of older samples, meaning it
overcomes the systematic underestimation of DNAm age in
the older that was observed with existing clocks. It is also
important to consider the distribution of ages in the training
dataset (e.g. minimum, maximum, median, first and third
quartiles), as this can influence the predictor and lead to
biases if not representative of the datasets it will be applied
to.
The importance of developing tissue-specific estimators is
supported by other recently developed tissue-specific clocks
including DNAm age predictors for whole blood (Zhang
et al., 2019), human skeletal muscle (Voisin et al., 2020)
and human bone (Gopalan et al., 2019), which all out per-
form pan-tissue clocks in samples from the specific tissues in
which they were trained. It is known that DNA methylation
patterns are distinct between tissue and cell types
(Mendizabal et al., 2019), and it is therefore not surprising
that DNAm age estimation models would differ in accuracy
across tissue types. As technologies for profiling DNAm in
purified cell populations from bulk tissue become more ac-
cessible, future clocks should be developed for purified pop-
ulations of individual cell-types to overcome issues of
cellular heterogeneity in complex tissues such as the brain.
Furthermore, our finding that the DNAmClockCortical, like
other clocks, is associated with the proportion of specific
cell-types in a given tissue sample highlights the importance
of covarying for cellular heterogeneity in all subsequent
analyses using values derived from epigenetic clocks.
Although a pan-tissue estimator such as Horvath’s
DNAmClockMulti has clear general utility, the trade-off be-
tween accuracy and practicality needs to be taken into con-
sideration depending on the hypothesized question being
tested. Applying one model across multiple tissues may lead
to a suboptimal fit (for example, when applying a linear
model where there is non-linearity), and the performance of
such a clock would need to be tested in individual tissue
types. To assess the linearity of DNAm age predictors we
investigated the association between DNAm age, and age
squared. Of note, as age explains less of the variation in
DNAm age in the second generation clocks (where the pri-
mary aim is to predict health outcomes) including the
DNAmClockPheno, adding an age-squared term may be an
unsuitable measure to address non-linearity where these pre-
dictors are applied. Adding the squared variable allowed us
to more accurately model the effect of age in the three first
generation clocks (where the primary aim is to predict age),
which could have a non-linear relationship with DNAm age.
The DNAmClockCortical was the most linear in terms of
fitting DNAm age against actual age. Although age squared
terms were significantly associated with DNAm age in the
testing data using all estimators, the higher significance of
the age squared term in the cortex-specific clock suggests
that of all the clocks, our model is the least biased.
However, as indicated by the relationship between DNAm
and age squared, we need to consider the possibility that fit-
ting a linear model might not be the best approach, and to
account for this possibility we recommend that future age-
acceleration analyses control for age squared terms. Because
of the nature of DNAm clocks, D age estimated using exist-
ing clocks is highly correlated with chronological age (El
Khoury et al., 2019). If age is not controlled for it could
lead to spurious associations with health outcomes, which
are driven by age and not the variable of interest.
Furthermore, as the prediction is less precise in older individ-
uals, even where DNAm is regressed on chronological age,
the residual may still be associated with age, potentially lead-
ing to false positive associations. Recent studies have found
associations between accelerated DNAm age in human brain
and neurodegenerative phenotypes (Levine et al., 2015,
2018). Our findings suggest that previous associations with
age-associated phenotypes may have been confounded by a
lack of robust calibration to estimate DNAm age in human
cortex from older donors; caution is warranted in interpret-
ing reported results that have been generated using a non-tis-
sue specific predictor. Future work will focus on applying
our novel DNAmClockCortical to existing cohorts with
DNAm data and detailed measures of neuropathology.
While DNAm age is a useful indicator of age, it may not be
the best indicator of health disparities between individuals
with brain disorders.
In summary, we show that previous epigenetic clocks sys-
tematically underestimate age in older samples and do not
perform as well in human cortex tissue. We developed a
novel epigenetic age model specifically for human cortex.
Our findings suggest that previous associations between pre-
dicted DNAm age and neurodegenerative phenotypes may
represent false positives resulting from suboptimal calibra-
tion of DNAm clocks for the tissue being tested and for phe-
notypes that manifest at older ages. The age distribution and
tissue type of samples included in training datasets need to
be considered when building and applying epigenetic clock
algorithms to human epidemiological or disease cohorts.
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